- Home
- INSM vs DOCS Comparison
INSM vs DOCS Comparison
Compare INSM & DOCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- DOCS
- Stock Information
- Founded
- INSM 1988
- DOCS 2010
- Country
- INSM United States
- DOCS United States
- Employees
- INSM N/A
- DOCS N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- DOCS Retail: Computer Software & Peripheral Equipment
- Sector
- INSM Health Care
- DOCS Technology
- Exchange
- INSM Nasdaq
- DOCS Nasdaq
- Market Cap
- INSM 12.6B
- DOCS 13.2B
- IPO Year
- INSM 2000
- DOCS 2021
- Fundamental
- Price
- INSM $65.08
- DOCS $59.17
- Analyst Decision
- INSM Strong Buy
- DOCS Buy
- Analyst Count
- INSM 16
- DOCS 16
- Target Price
- INSM $95.36
- DOCS $64.94
- AVG Volume (30 Days)
- INSM 2.5M
- DOCS 1.8M
- Earning Date
- INSM 05-08-2025
- DOCS 05-15-2025
- Dividend Yield
- INSM N/A
- DOCS N/A
- EPS Growth
- INSM N/A
- DOCS 49.41
- EPS
- INSM N/A
- DOCS 1.00
- Revenue
- INSM $381,030,000.00
- DOCS $550,168,000.00
- Revenue This Year
- INSM $30.36
- DOCS $21.45
- Revenue Next Year
- INSM $115.55
- DOCS $12.37
- P/E Ratio
- INSM N/A
- DOCS $58.88
- Revenue Growth
- INSM 20.77
- DOCS 17.47
- 52 Week Low
- INSM $21.92
- DOCS $22.96
- 52 Week High
- INSM $84.91
- DOCS $85.21
- Technical
- Relative Strength Index (RSI)
- INSM 35.80
- DOCS 55.39
- Support Level
- INSM $63.81
- DOCS $56.76
- Resistance Level
- INSM $73.39
- DOCS $60.10
- Average True Range (ATR)
- INSM 2.53
- DOCS 1.80
- MACD
- INSM -0.38
- DOCS 0.70
- Stochastic Oscillator
- INSM 13.26
- DOCS 82.81
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
About DOCS Doximity Inc.
Doximity Inc is a digital platform for U.S. medical professionals. Its cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers.